患有年轻发病的帕金森症患者的焦点 dystonia:一个诊断挑战
Ahmer A Longi1, Pushparaja Shetty2, Misbah Fazlani1
1Internal Medicine, Mediclinic Welcare Hospital, Dubai, ARE.
Cureus
|August 18, 2025
概括
口腔 dystonia (OPD),一种影响面部和舌头肌肉的运动障碍,在早期帕金森病 (PD) 中经常错过. 在PD患者中及时诊断和治疗OPD显著改善了结果和生活质量.
科学领域:
- 神经学 神经学
- 运动障碍 运动障碍
背景情况:
- 口腔 dystonia (OPD) 涉及面部,唇部和舌头肌肉的非自愿运动.
- OPD经常被低诊断,即使是在早期的帕金森病 (PD) 中.
- 有限的认识有助于患者和医疗保健提供者的诊断延迟.
研究的目的:
- 强调识别口腔 dystonia (OPD) 作为帕金森病 (PD) 的早期迹象的重要性.
- 介绍早期发病的PD与OPD的案例研究,并讨论诊断和管理策略.
- 为了检查早期发病的PD中 dystonia 的特征,患病率和临床表现.
主要方法:
- 一个45岁的阿联男性的病例报告,患有静止震和渐进的舌.
- 根据运动障碍学会2015年临床诊断标准的临床和放射检查.
- 启动多巴胺疗法以治疗症状.
主要成果:
- 该患者被诊断出患有早期发病的临床确定的帕金森病 (PD).
- 多巴胺类疗法导致患者口腔 dystonia 和震的显著改善.
- 这个案例强调了OPD可能是PD的早期,可治疗的表现.
结论:
- 在帕金森病 (PD) 中,早期识别和及时干预口腔 dystonia (OPD) 是至关重要的.
- 在早期发病的PD中,OPD可能会带来诊断挑战,但对治疗反应良好.
- 识别像OPD这样的非典型特征可以提高患者的治疗结果和生活质量.
相关概念视频
Parkinson's Disease: Treatment
377
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
377
Parkinson's Disease: Overview
703
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
703
Myasthenia Gravis: Diagnostic Tests
1.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K
Neural Regulation
39.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.9K
Disorders of the Skeletal Muscle
1.1K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.1K
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K


